The growing burden of rebates and discounts has left drugmakers “underwater” on manufacturing inexpensive, generic cancer drugs, and has significantly harmed the supply chain for these treatments, the Community Oncology Alliance (COA) said in a recent statement.
Source: Drug Industry Daily